The increasing role of mass spectrometry in quantitative clinical proteomics

Clinical Chemistry

Volumn 56, Issue 9, 2010, Pages 1373-1374

  Whiteaker, Jeffrey R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY AFFINITY; CARBOXY TERMINAL SEQUENCE; EDITORIAL; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEOMICS;

CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; MICROFLUIDIC ANALYTICAL TECHNIQUES; NANOTECHNOLOGY; PEPSIN A; PEPSINOGEN A; PROTEOMICS; SALIVA;

EID: 77956361828     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.150383     Document Type: Editorial

References (15)

1. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
2. Severino ME, Dubose RF, Patterson SD. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development. IDrugs 2006;9:849-53.
3. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004;10:3885-96.
4. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177-85.
5. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24: 971-83.
6. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein bio-marker pipeline. Proteomics Clin Appl 2008;2:1386-402.
7. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1229-39.
8. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
9. Want EJ, Cravatt BF, Siuzdak G. The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem 2005;6:1941-51. (Pubitemid 41598162)
10. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005; 38:296-309.
11. Neubert H, Gale J, Muirhead D. Online high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS: assay development for total salivary pepsin/pepsinogen. Clin Chem 2010;56:1413-23.
12. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007;4:175-86.
13. Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem 2010;56:165-71.
14. Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, et al., on behalf of the Workshop Participants. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA Interagency Oncology Task Force on Molecular Diagnostics. Clin Chem 2010;56:237-43.
15. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, Patterson SD, et al. A human proteome detection and quantitation project. Mol Cell Proteomics 2009;8:883-6.